Intent To Grant an Exclusive License of a U.S. Government-Owned Patent

Riepilogo

In accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(I)(i), announcement is made of the intent to grant an exclusive, royalty- bearing, revocable license to U.S. patent number 6,387,665 issued May 14, 2002 entitled "Method of Making a Vaccine for Anthrax," and U.S. patent number 6,316,006 issued November 13, 2001 entitled "Asporogenic B. Anthracis Expression System" to VaxGen, Inc. with its principal place of business at 1000 Marina Blvd., Suite 200, Brisbane, Ca 94005. The exclusive field of use will be in field of preventive vaccines against anthrax infection.